{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:01:38Z","timestamp":1776434498851,"version":"3.51.2"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2009,6,18]],"date-time":"2009-06-18T00:00:00Z","timestamp":1245283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite the prevalence of anemia in cancer, recombinant erythropoietin (Epo) has declined in use because of recent Phase III trials showing more rapid cancer progression and reduced survival in subjects randomized to Epo. Since Epo receptor (EpoR), Jak2, and Hsp70 are well-characterized mediators of Epo signaling in erythroid cells, we hypothesized that Epo might be especially harmful in patients whose tumors express high levels of these effectors. Because of the insensitivity of immunohistochemistry for detecting low level EpoR protein, we developed assays to measure levels of EpoR, Jak2 and Hsp70 mRNA in formalin-fixed paraffin-embedded (FFPE) tumors. We tested 23 archival breast tumors as well as 136 archival head and neck cancers from ENHANCE, a Phase III trial of 351 patients randomized to Epo versus placebo concomitant with radiotherapy following complete resection, partial resection, or no resection of tumor. EpoR, Jak2, and Hsp70 mRNA levels varied &amp;gt;30-fold, &amp;gt;12-fold, and &amp;gt;13-fold across the breast cancers, and &amp;gt;30-fold, &amp;gt;40-fold, and &amp;gt;30-fold across the head and neck cancers, respectively. Locoregional progression-free survival (LPFS) did not differ among patients whose head and neck cancers expressed above- versus below-median levels of EpoR, Jak2 or Hsp70, except in the subgroup of patients with unresected tumors (n = 28), where above-median EpoR, above-median Jak2, and below-median Hsp70 mRNA levels were all associated with significantly poorer LPFS. Our results provide a framework for exploring the relationship between Epo, cancer progression, and survival using archival tumors from other Phase III clinical trials.<\/jats:p>\n               <jats:p>Disclosure of potential conflicts of interest is found at the end of this article.<\/jats:p>","DOI":"10.1002\/stem.156","type":"journal-article","created":{"date-parts":[[2009,6,18]],"date-time":"2009-06-18T23:54:15Z","timestamp":1245369255000},"page":"2353-2361","source":"Crossref","is-referenced-by-count":24,"title":["Evaluating Erythropoietin-Associated Tumor Progression Using Archival Tissues from a Phase III Clinical Trial"],"prefix":"10.1093","volume":"27","author":[{"given":"Chris P.","family":"Miller","sequence":"first","affiliation":[{"name":"Department of Medicine\/Hematology and the Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Valliant-Saunders","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Hematology and the Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joringel F.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Hematology and the Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Mattern","sequence":"additional","affiliation":[{"name":"Department of Radiooncology, University Clinic, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Urban","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Henke","sequence":"additional","affiliation":[{"name":"Department of Radiooncology, University Clinic, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Anthony","family":"Blau","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Hematology and the Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,6,18]]},"reference":[{"key":"2022011221423198600_bib1","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"key":"2022011221423198600_bib2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"JAMA"},{"key":"2022011221423198600_bib3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"2022011221423198600_bib4","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022011221423198600_bib5","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","article-title":"Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia","volume":"25","author":"Wright","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022011221423198600_bib6","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","article-title":"Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022011221423198600_bib7","author":"Oncologic Drugs Advisory Committee meeting briefing materials","year":"2008"},{"key":"2022011221423198600_bib8","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1634\/stemcells.2007-0229","article-title":"Erythropoietin in cancer: Presumption of innocence?","volume":"25","author":"Blau","year":"2007","journal-title":"Stem Cells"},{"key":"2022011221423198600_bib9","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-08-0264","article-title":"Erythropoiesis-stimulating agent use in cancer: Preclinical and clinical perspectives","volume":"14","author":"Arcasoy","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022011221423198600_bib10","first-page":"3561","article-title":"Erythropoietin and erythropoietin receptor expression in human cancer","volume":"61","author":"Acs","year":"2001","journal-title":"Cancer Res"},{"key":"2022011221423198600_bib11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cncr.22832","article-title":"Expression and function of erythropoietin receptors in tumors: Implications for the use of erythropoiesis-stimulating agents in cancer patients","volume":"110","author":"Sinclair","year":"2007","journal-title":"Cancer"},{"key":"2022011221423198600_bib12","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cellsig.2006.08.014","article-title":"A \u201cclassical\u201d homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells","volume":"19","author":"Um","year":"2007","journal-title":"Cell Signal"},{"key":"2022011221423198600_bib13","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2006.06.2737","article-title":"Do erythropoietin receptors on cancer cells explain unexpected clinical findings?","volume":"24","author":"Henke","year":"2006","journal-title":"J Clin Oncol"},{"key":"2022011221423198600_bib14","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood-2005-10-4066","article-title":"Anti-Epo receptor antibodies do not predict Epo receptor expression","volume":"107","author":"Elliott","year":"2006","journal-title":"Blood"},{"key":"2022011221423198600_bib15","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0406491101","article-title":"Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor","volume":"101","author":"Brines","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011221423198600_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.gde.2006.12.009","article-title":"Jak2: normal function and role in hematopoietic disorders","volume":"17","author":"Ihle","year":"2007","journal-title":"Curr Opin Genet Dev"},{"key":"2022011221423198600_bib17","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1097-2765(01)00401-4","article-title":"The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor","volume":"8","author":"Huang","year":"2001","journal-title":"Mol Cell"},{"key":"2022011221423198600_bib18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/35088074","article-title":"Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades","volume":"412","author":"Digicaylioglu","year":"2001","journal-title":"Nature"},{"key":"2022011221423198600_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1391.018","article-title":"New tricks for an old dog: The evolving world of Hsp70","volume":"1113","author":"Morano","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"2022011221423198600_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1196\/annals.1391.030","article-title":"Heat shock proteins in cancer","volume":"1113","author":"Sherman","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"2022011221423198600_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature05378","article-title":"HSP70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1","volume":"445","author":"Ribeil","year":"2007","journal-title":"Nature"},{"key":"2022011221423198600_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archotol.130.1.21","article-title":"Molecular assay to detect metastatic head and neck squamous cell carcinoma","volume":"130","author":"Becker","year":"2004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2022011221423198600_bib23","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1073\/pnas.0610117104","article-title":"Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma","volume":"104","author":"Prince","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011221423198600_bib24","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1593\/neo.07694","article-title":"Effects of recombinant erythropoietin on breast cancer-initiating cells","volume":"9","author":"Phillips","year":"2007","journal-title":"Neoplasia"},{"key":"2022011221423198600_bib25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(85)80053-2","article-title":"Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo","volume":"41","author":"Palacios","year":"1985","journal-title":"Cell"},{"key":"2022011221423198600_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.exphem.2005.09.012","article-title":"Chemokine expression in human erythroid leukemia cell line AS-E2: Macrophage inflammatory protein-3alpha\/CCL20 is induced by inflammatory cytokines","volume":"34","author":"Inoue","year":"2006","journal-title":"Exp Hematol"},{"key":"2022011221423198600_bib27","doi-asserted-by":"crossref","first-page":"RESEARCH0034","DOI":"10.1186\/gb-2002-3-7-research0034","article-title":"Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes","volume":"3","author":"Vandesompele","year":"2002","journal-title":"Genome Biol"},{"key":"2022011221423198600_bib28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.lungcan.2005.10.020","article-title":"Pre-operative plasma erythropoietin concentration and survival following surgery for non-small cell lung cancer","volume":"51","author":"Paul","year":"2006","journal-title":"Lung Cancer"},{"key":"2022011221423198600_bib29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.bbrc.2008.12.146","article-title":"Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway","volume":"379","author":"Fu","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"2022011221423198600_bib30","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/labinvest.3700303","article-title":"Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization","volume":"85","author":"Antonov","year":"2005","journal-title":"Lab Invest"},{"key":"2022011221423198600_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/01.pai.0000213105.18569.fa","article-title":"Geometry of human vascular system: is it an obstacle for quantifying antiangiogenic therapies?","volume":"15","author":"Grizzi","year":"2007","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2022011221423198600_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63093-3","article-title":"Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay","volume":"164","author":"Cronin","year":"2004","journal-title":"Am J Pathol"},{"key":"2022011221423198600_bib33","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.bjc.6604220","article-title":"Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells","volume":"98","author":"Sinclair","year":"2008","journal-title":"Br J Cancer"},{"key":"2022011221423198600_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2052.2005.01233.x","article-title":"Allelic variation in the erythropoietin receptor gene is associated with uterine capacity and litter size in swine","volume":"36","author":"Vallet","year":"2005","journal-title":"Anim Genet"},{"key":"2022011221423198600_bib35","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine\u2013reporting of subgroup analyses in clinical trials","volume":"357","author":"Wang","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fstem.156","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fstem.156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/stem.156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/stem.156","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/27\/9\/2353\/41948518\/stmcls_27_9_2353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/27\/9\/2353\/41948518\/stmcls_27_9_2353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:51:29Z","timestamp":1642560689000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/27\/9\/2353-2361\/6420063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,18]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,6,18]]},"published-print":{"date-parts":[[2009,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/stem.156","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,9,1]]},"published":{"date-parts":[[2009,6,18]]}}}